Highest-materiality recent filing
FDA accepts NDA for BBP-418 with Priority Review; PDUFA Nov 27, 2026
FDA accepted NDA with Priority Review for BBP-418 to treat LGMD2I/R9; PDUFA target action date November 27, 2026.
NDA submitted for encaleret, a potential first approved therapy for autosomal dominant hypocalcemia type 1 (ADH1).
BridgeBio Pharma establishes $500M at-the-market equity offering program
Up to $500M in common stock may be sold via ATM through Goldman Sachs and Leerink Partners.
BridgeBio Q1 rev $194.5M, Attruby sales $180.6M; $500M share buyback authorized
Q1 2026 total revenues net $194.5M, up from $116.6M YoY; Attruby U.S. net product revenue $180.6M.
BridgeBio submits NDA to FDA for BBP-418 for LGMD2I/R9; potential first approved therapy
NDA submission for oral BBP-418 in limb-girdle muscular dystrophy type 2I/R9.
BridgeBio reports Q4 net product revenue $146M; three positive Phase 3 trials
Q4 net loss $192.9M ($1.00/share); FY net loss $724.9M ($3.78/share).
BridgeBio reports positive Phase 3 infigratinib results in achondroplasia; NDA/MAA planned H2 2026
PROPEL 3 met primary endpoint: change from baseline in AHV at Week 52 (p<0.0001); mean treatment difference +2.10 cm/year.
BridgeBio issues $632.5M of 0.75% convertible notes due 2033, prefunds repayment of 2027 notes
Aggregate $632.5M principal (incl. $82.5M initial purchasers' option), 0.75% coupon, due Feb 1, 2033.
BridgeBio reports Q4 Attruby revenue $146M, cash $587.5M; plans two NDAs in H1 2026
Preliminary unaudited Q4 2025 Attruby net revenue $146M; full year $362.4M; cash, equivalents and securities $587.5M as of Dec 31, 2025.
BridgeBio reports positive Phase 3 results for encaleret in ADH1; 76% met primary endpoint
76% of encaleret-treated patients achieved both serum and urine calcium targets vs 4% on conventional therapy (p<0.0001).
Total revenue $120.7M (Q3 2024: $2.7M), driven by $108.1M Attruby net product revenue.
BridgeBio Phase 3 FORTIFY study hits all primary and secondary endpoints for BBP-418 in LGMD2I/R9
Primary endpoint: glycosylated αDG increased 1.8x from baseline at 3 months (p<0.0001); sustained at 12 months.
BridgeBio Q2 2025 rev $110.6M, Attruby sales $71.5M, net loss $181.9M
Total revenue $110.6M vs $2.2M prior year; Attruby net product revenue $71.5M.
BridgeBio monetizes EU acoramidis royalties for $300M cash; caps future payments
Eidos sold right to receive certain royalties on acoramidis net sales in EU and EPO states to ARS and LSI Financing Fund.
BridgeBio Q1: $36.7M Attruby revenue, net loss $167.4M, pipeline advances
First full quarter of Attruby net product revenue $36.7M; 2,072 prescriptions from 756 prescribers since Nov 2024 FDA approval.
BridgeBio Pharma appoints Thomas Trimarchi as President and CFO; former CFO departs
Brian Stephenson's employment ended March 17, 2025; receives 9 months base salary and COBRA.
BridgeBio closes $575M 1.75% convertible notes due 2031; refinances Blue Owl secured debt
Issued $575M aggregate principal of 1.75% convertible senior notes due March 1, 2031.
Attruby (acoramidis) prescriptions reached 1,028 from 516 prescribers as of Feb 17; EU approval on Feb 10 triggered $75M milestone.
Attruby (acoramidis) approved Nov 22, 2024; 430 prescriptions by 248 unique HCPs since launch.
FDA approves BridgeBio's Attruby (acoramidis) for ATTR-CM to reduce CV death and hospitalization
Attruby is first and only approved TTR stabilizer with label specifying near-complete stabilization (≥90%).
BridgeBio posts Q3 net loss of $162M; acoramidis PDUFA set for Nov 29, 2024
Net loss per share of $0.86; revenue $2.7M vs $4.1M YoY; operating expenses $194.5M.
Phase 1/2 ADventure trial of BBP-631 in classic CAH: increased endogenous cortisol in all higher-dose patients (max change 6.6 µg/dL post-ACTH); well tolerated with no treatment-related SAEs.
BridgeBio forms GondolaBio JV with $300M investor commitment; retains 45% stake
BridgeBio contributed early-stage programs for Erythropoietic Protoporphyria, Alpha-1 Antitrypsin Deficiency, and Tuberous Sclerosis Complex.
BridgeBio Q2 net loss $73.5M ($0.39/sh), NDA for acoramidis filed with PDUFA Nov 29
Net loss $73.5M ($0.39/sh) vs $157.9M loss a year ago; Q2 revenue $2.2M, H1 revenue $213.3M from Bayer and Kyowa Kirin deals.
Cohort 5 (0.25 mg/kg/day) showed sustained AHV increase: +2.51 cm/yr at Month 12, +2.50 cm/yr at Month 18 (p=0.0015).
BridgeBio Q1 rev $211M, net loss narrows; secures $1.5B; launches BBOT
Revenue $211.1M vs $1.8M YoY; net loss $35.2M vs $140.2M prior year.
The employment of Brian C. Stephenson, the Chief Financial Officer of BridgeBio Pharma, Inc. (the “Company”), ended on March 17, 2025 (the “Effective Date”).
Neil Kumar, Ph.D. stepped down as President
Thomas Trimarchi was appointed as the Company’s President and Chief Operating Officer
Max materiality 1.00 · Median 0.80 · Most common event other_material